SYN818 for advanced solid tumors with DNA repair defects
Part of Cancer, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced or metastatic and no longer responding to available standard therapies.
- You must have a BRCA mutation or another DNA repair deficiency in your tumor or blood.
- You should be able to provide a tumor tissue or blood sample for testing.
- You must have at least one measurable tumor (visible on scans).
- You cannot have had a POLQ inhibitor before, or have certain other cancers or serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SYN608, in people with advanced or metastatic solid tumors, including breast and ovarian cancer, who have run out of standard treatment options. The drug targets tumors with BRCA mutations or other DNA repair problems, which may make them more sensitive to this treatment.
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
This trial tests a new pill called ASN-3186 for people with advanced solid tumors that haven't responded to standard treatments. The drug may work especially well if your cancer has certain DNA repair problems, like a BRCA mutation.
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
This trial tests a new drug called HRS-6208 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the cancer.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.